hrs4r
 I want to donate

SARA VERDURA MARTINEZ

Firma
SARA VERDURA-MARTINEZ
Position
Investigador/a Pre-doctoral – R1
Predoctoral Researchers – R1

Projectes

Codi oficial: CP20/00003 Start date:01/01/2021 Data fi: 31/12/2025 Investigador/a principal: ELISABET CUYÀS NAVARRO, JAVIER ABEL MENÉNDEZ MENÉNDEZ Organisme finançador: INSTITUTO DE SALUD CARLOS III
Codi oficial: PI22/00297 Start date:01/01/2023 Data fi: 31/12/2025 Investigador/a principal: JAVIER ABEL MENÉNDEZ MENÉNDEZ, ELISABET CUYÀS NAVARRO Organisme finançador: INSTITUTO DE SALUD CARLOS III
Codi oficial: 2021 SGR 01507 Start date:01/01/2022 Data fi: 30/06/2025 Investigador/a principal: BEGOÑA MARTIN CASTILLO Organisme finançador: AGENCIA DE GESTIO D'AJUTS UNIV. I RECER.
Codi oficial: PID2022-141955OB-I00 Start date:17/10/2023 Data fi: 31/08/2026 Investigador/a principal: JAVIER ABEL MENÉNDEZ MENÉNDEZ Organisme finançador: MINISTERIO DE ECONOMIA Y COMPETITIVIDAD MINECO /

Publicacions

Menendez JA, Cuyàs E, Encinar JA, Steen TV, Verdura S, Llop-Hernández À, López J, Serrano-Hervás E, Osuna S, Martin-Castillo B, Lupu R

The Fatty Acid Synthase (FASN) signalome: A molecular guide for precision oncology.

MOLECULAR ONCOLOGY, 2024, 18, 479-516 dx.doi.org/10.1002/1878-0261.13582
Teixidor E, Sais E, Vásquez CA, Carbajal W, Hernández A, Sánchez G, Izquierdo A, Verdura S, Menéndez JA, Bosch-Barrera J

Addendum: Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma.

Oncotarget, 2023, 14, 668-668 dx.doi.org/10.18632/oncotarget.28471
Bosch-Barrera J, Roqué A, Teixidor E, Carmona-Garcia MC, Arbusà A, Brunet J, Martin-Castillo B, Cuyàs E, Verdura S, Menendez JA

Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin

Pharmaceuticals, 2022, 15 dx.doi.org/10.3390/ph15010019
Espinoza I, Yang L, Steen TV, Vellon L, Cuyàs E, Verdura S, Lau L, Menendez JA, Lupu R

Binding of the angiogenic/senescence inducer CCN1/CYR61 to integrin alpha(6)beta(1) drives endocrine resistance in breast cancer cells

Aging-Us, 2022, 14, 1200-1213 dx.doi.org/10.18632/aging.203882
Yang, L, Vander Steen, T, Espinoza, I, Cuyas, E, Verdura, S, Menendez, JA, Lupu, R

Nuclear moonlighting of the secreted growth factor heregulin drives endocrine-resistant breast cancer independently of HER2/HER3 signaling

AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12, 2173-2188
Llop-Hernández À, Verdura S, Cuyàs E, Menendez JA

Nutritional Niches of Cancer Therapy-Induced Senescent Cells

Nutrients, 2022, 14 dx.doi.org/10.3390/nu14173636
Verdura S, Encinar JA, Fernández-Arroyo S, Joven J, Cuyàs E, Bosch-Barrera J, Menendez JA

Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 dx.doi.org/10.3390/ijms23179986
Verdura S, Encinar JA, Teixidor E, Segura-Carretero A, Micol V, Cuyàs E, Bosch-Barrera J, Menendez JA

Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors

Cancers, 2022, 14 dx.doi.org/10.3390/cancers14246101
Espinoza I, Kurapaty C, Park CH, Vander Steen T, Kleer CG, Wiley E, Rademaker A, Cuyàs E, Verdura S, Buxó M, Reynolds C, Menendez JA, Lupu R

Depletion of CCN1/CYR61 reduces triple-negative/basal-like breast cancer aggressiveness

AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12, 839-851
Cuyàs E, Fernández-Arroyo S, Verdura S, Lupu R, Joven J, Menendez JA

Metabolomic and Mitochondrial Fingerprinting of the Epithelial-to-Mesenchymal Transition (EMT) in Non-Tumorigenic and Tumorigenic Human Breast Cells

Cancers, 2022, 14 dx.doi.org/10.3390/cancers14246214

Formulari de contacte

About IDIBGI!

menu